Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hedgehog Inhibitor”

54 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 54 results

Early research (Phase 1)Study completedNCT02151864
What this trial is testing

LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A/B7 Cirrhosis

Who this might be right for
Hepatocellular CarcinomaCirrhosis
Jason K. Sicklick, M.D. 9
Testing effectiveness (Phase 2)Study completedNCT01174264
What this trial is testing

Evaluation of Food Effect on Pharmacokinetics of Vismodegib

Who this might be right for
Malignant Neoplasm
National Cancer Institute (NCI) 63
Early research (Phase 1)Study completedNCT03434262
What this trial is testing

SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors

Who this might be right for
Anaplastic AstrocytomaAnaplastic EpendymomaAnaplastic Ganglioglioma+53 more
St. Jude Children's Research Hospital 68
Very early researchUnknownNCT01713218
What this trial is testing

Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Vismodegib Before Surgery in Pancreatic Cancer

Who this might be right for
Pancreatic Adenocarcinoma Resectable
Jean-Luc Van Laethem 21
Not applicableWithdrawnNCT01911416
What this trial is testing

A Biomarker Study to Identify Predictive Signatures of Response to LDE225 (Hedgehog Inhibitor) In Patients With Resectable Pancreatic Cancer

Who this might be right for
Pancreatic Ductal Adenocarcinoma
University of Utah
Testing effectiveness (Phase 2)Study completedNCT01842646
What this trial is testing

Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS)

Who this might be right for
Myelodysplastic Syndrome (MDS)Chronic Myelomonocytic Leukemia (CMML)
H. Lee Moffitt Cancer Center and Research Institute 35
Testing effectiveness (Phase 2)Looking for participantsNCT05538091
What this trial is testing

Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Who this might be right for
Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Primary Peritoneal CarcinomaPARP Inhibitor+1 more
Ronald Buckanovich 48
Early research (Phase 1)Study completedNCT00880308
What this trial is testing

Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumor CancersMedulloblastomaBasal Cell Carcinoma
Novartis Pharmaceuticals 103
Testing effectiveness (Phase 2)Study completedNCT00833417
What this trial is testing

A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma

Who this might be right for
Basal Cell Carcinoma
Genentech, Inc. 104
Testing effectiveness (Phase 2)Study completedNCT03132636
What this trial is testing

PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy

Who this might be right for
Carcinoma, Basal Cell
Regeneron Pharmaceuticals 138
Early research (Phase 1)Study completedNCT01546519
What this trial is testing

Vismodegib in Patients With Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic Function

Who this might be right for
Cancer
Genentech, Inc. 31
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07578337
What this trial is testing

A Clinical Study Evaluating a New Treatment Strategy for Patients With Advanced Pancreatic Cancer Who Have Not Received Prior Treatment for Advanced Disease.

Who this might be right for
UntreatedAdvanced Pancreatic Cancer
Nelum Corp 40
Early research (Phase 1)Study completedNCT01576666
What this trial is testing

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

Who this might be right for
Dose EscalationSafetyPreliminary Efficacy+9 more
Novartis Pharmaceuticals 120
Early research (Phase 1)Study completedNCT02038777
What this trial is testing

PF-04449913 In Japanese Patients With Select Hematologic Malignancies

Who this might be right for
Acute Myeloid Leukemia
Pfizer 48
Testing effectiveness (Phase 2)Study completedNCT01088815
What this trial is testing

Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas

Who this might be right for
Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 98
Testing effectiveness (Phase 2)Study completedNCT00636610
What this trial is testing

Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Genentech, Inc. 199
Testing effectiveness (Phase 2)WithdrawnNCT01757327
What this trial is testing

LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer

Who this might be right for
Breast Neoplasms
Washington University School of Medicine
Large-scale testing (Phase 3)Study completedNCT03416179
What this trial is testing

A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia

Who this might be right for
Leukemia, Myeloid, Acute
Pfizer 730
Testing effectiveness (Phase 2)Study completedNCT00739661
What this trial is testing

Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission

Who this might be right for
Ovarian Cancer
Genentech, Inc. 104
Early research (Phase 1)Study completedNCT01209143
What this trial is testing

Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists

Who this might be right for
Solid Cancers
Genentech, Inc. 52
Next Page